Explore the words cloud of the THERADNET project. It provides you a very rough idea of what is the project "THERADNET" about.
The following table provides information about the project.
|Coordinator Country||Switzerland [CH]|
|Total cost||4˙026˙324 €|
|EC max contribution||4˙026˙324 € (100%)|
1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
|Duration (year-month-day)||from 2019-09-01 to 2023-08-31|
Take a look of project's partnership.
|1||UNIVERSITAT ZURICH||CH (ZURICH)||coordinator||562˙553.00|
|2||THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD||UK (OXFORD)||participant||606˙345.00|
|3||INSTITUT CURIE||FR (PARIS)||participant||549˙604.00|
|4||UNIVERSITEIT MAASTRICHT||NL (MAASTRICHT)||participant||531˙239.00|
|5||UNIVERSITE CATHOLIQUE DE LOUVAIN||BE (LOUVAIN LA NEUVE)||participant||512˙640.00|
|6||TECHNISCHE UNIVERSITAET DRESDEN||DE (DRESDEN)||participant||505˙576.00|
|7||UNIVERSITAETSKLINIKUM ESSEN||DE (ESSEN)||participant||505˙576.00|
|8||WESTDEUTSCHES PROTONENTHERAPIEZENTRUM ESSEN (WPE) GGMBH||DE (ESSEN)||participant||252˙788.00|
Radiotherapy alone or in multimodality approaches is applied in 45-60% of all cancer patients, but despite technical innovations approximately only 50% are cured. Disease recurrence may be due to regrowth of the primary tumor or metastatic outgrowth. Intrinsic and acquired resistance of the tumor and adverse reactions in the co-irradiated surrounding normal tissues dampen a successful therapy outcome. Substantial improvements are now expected from biologically optimized, personalized radiotherapy. This network is built on the premises that integration of novel-emerging radiobiological and tumor-biological concepts into current standard-of-care will improve outcome of radiotherapy-treated cancer patients. As the field of radiobiology is small in individual countries, it is essential to cooperate on the European level to achieve a critical mass for innovation in research and training. The partners in this network will stimulate outstanding science to understand the plasticity of an altered tumor metabolism and tumor microenvironment, including the immune system, prior to, and in response to radiotherapy, as well as related dose-limiting adverse effects in normal tissues. Research and development of novel combined treatment modalities in these areas will be performed in models as close as possible to the clinical situation to evaluate their potential to widen the therapeutic window beyond standard-of-care. Students will benefit from outstanding expertise and collaborations within academia and industry integrating novel concepts into translational cancer and radiation research. This will guarantee high employability in various sectors of cancer research and precision medicine. The European community will benefit from the pursuit of innovative hypotheses, training of new researchers, and dissemination of knowledge. By combatting a major death-related disease in Europe, this project will raise health and bring long-term benefit to the European and international community.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERADNET" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "THERADNET" are provided by the European Opendata Portal: CORDIS opendata.
Big Data Challenges for MathematicsRead More
Training research pioneers by utilizing and validating the promise of electroporation for minimal invasive oncological treatments.Read More
Glyco-Nanoparticles for Applications in Advance NanomedicineRead More